%0 Journal Article
%T Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment.
%A Levine AB
%A Nobre L
%A Das A
%A Milos S
%A Bianchi V
%A Johnson M
%A Fernandez NR
%A Stengs L
%A Ryall S
%A Ku M
%A Rana M
%A Laxer B
%A Sheth J
%A Sbergio SG
%A Fedoráková I
%A Ramaswamy V
%A Bennett J
%A Siddaway R
%A Tabori U
%A Hawkins C
%J Nat Commun
%V 15
%N 1
%D 2024 Jul 10
%M 38987542
%F 17.694
%R 10.1038/s41467-024-49595-1
%X With the success of immunotherapy in cancer, understanding the tumor immune microenvironment (TIME) has become increasingly important; however in pediatric brain tumors this remains poorly characterized. Accordingly, we developed a clinical immune-oncology gene expression assay and used it to profile a diverse range of 1382 samples with detailed clinical and molecular annotation. In low-grade gliomas we identify distinct patterns of immune activation with prognostic significance in BRAF V600E-mutant tumors. In high-grade gliomas, we observe immune activation and T-cell infiltrates in tumors that have historically been considered immune cold, as well as genomic correlates of inflammation levels. In mismatch repair deficient high-grade gliomas, we find that high tumor inflammation signature is a significant predictor of response to immune checkpoint inhibition, and demonstrate the potential for multimodal biomarkers to improve treatment stratification. Importantly, while overall patterns of immune activation are observed for histologically and genetically defined tumor types, there is significant variability within each entity, indicating that the TIME must be evaluated as an independent feature from diagnosis. In sum, in addition to the histology and molecular profile, this work underscores the importance of reporting on the TIME as an essential axis of cancer diagnosis in the era of personalized medicine.